Gene therapy is linked to better nonmotor outcomes in spinal muscular atrophy type 1 compared to first-line nusinersen, new ...

The Muscular Dystrophy Association (MDA) today kicked off its largest annual MDA Holiday Retail Campaign, spanning thousands of retail ...

In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to ...

The Supreme Court on Friday dismissed Swiss drugmaker Roche’s appeal challenging Delhi High Court orders that refused to ...

With this judgment, Natco Pharma can now sell the Spinal Muscular Atrophy treatment drug for ₹15,900 compared to the previous ...

Imagine a child born in a family with a rare disease, whose treatment would cost more than 17 crore for a single dose. The ...

The parents of two boys born with a rare genetic disorder have demanded the rollout of a life-changing heel prick test – ...

Nearly all children with spinal muscular atrophy who started on Evrysdi before symptom onset are walking after three years, ...

Roche sued Natco in early 2024 after learning that the Hyderabad-based company plans to launch a lower-cost generic version ...

For people with spinal muscular atrophy, physical therapy can help support mobility, strength, and quality of life, regardless of SMA type.

Supreme Court dismisses Roche's petition, allowing NATCO Pharma to sell affordable spinal muscular atrophy drug in India.

In a major escalation of the patent battle over a life-saving rare disease drug, Swiss pharmaceutical giant F. Hoffmann-La ...